Share
𝕏 Facebook LinkedIn

Enhanced Antiproliferative Activity of Docetaxel by Extremely Low Frequency Electromagnetic Fields in MCF-7 Breast Cancer Cells.

AI: Melanie Research RF Safe Research Library Jan 1, 2025 NEUTRAL LOW

This in vitro study tested whether extremely low-frequency electromagnetic fields (50 Hz, 20 mT) enhance docetaxel effects in MCF-7 breast cancer cells. The authors report that combining ELF-EMF with docetaxel produced a similar reduction in cell viability at a lower docetaxel concentration than docetaxel alone, alongside G2/M arrest, apoptosis, and increased ROS. The findings are presented as supporting ELF-EMF as a potential chemotherapy-enhancing approach under the studied conditions.

Key points

  • The study exposed MCF-7 breast cancer cells to 50 Hz, 20 mT ELF-EMF with docetaxel.
  • Cell viability was assessed by MTT, and apoptosis, ROS, and cell cycle were measured by flow cytometry.
  • Docetaxel alone at 50 μM reduced viability by 50% in the reported conditions.
  • The combination of ELF-EMF and docetaxel achieved a similar 50% viability reduction at 14 μM docetaxel.
  • Combined treatment was associated with G2/M arrest and apoptotic cell death.
  • ROS levels were elevated in the combined treatment group, per flow cytometry.
  • Apoptosis-related morphology was examined using AO/PI staining and fluorescence microscopy.

Referenced studies & papers

Source: Open original

AI-generated summaries may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.